SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow JonesApr 16 13:38 ET
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Compass Therapeutics (CMPX)
TipRanksApr 16 10:00 ET
Express News | Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target
Moomoo 24/7Apr 16 07:41 ET
Express News | SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus Far
Moomoo 24/7Apr 16 07:17 ET
Express News | SAB Biotherapeutics: Completed Dosing Third Cohort for SAB-142 With No Observation of Serum Sickness Thus Far
Moomoo 24/7Apr 16 07:15 ET
Express News | SAB Biotherapeutics Provides SAB-142 Trial Update
Moomoo 24/7Apr 16 07:15 ET
SAB Biotherapeutics Advances SAB-142 in Phase One Trials
TipRanksApr 15 17:33 ET
Express News | SAB Biotherapeutics: on April 12, Completed Dosing of Cohort 3 for Phase One Trials of SAB-142, Has Not Observed Any Instances of Serum Sicknesses
Moomoo 24/7Apr 15 17:16 ET
SAB Biotherapeutics to Present at INNODIA Annual Meeting
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is
GlobeNewswireApr 8 07:15 ET
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human
GlobeNewswireApr 4 07:15 ET
SAB Biotherapeutics: Strong Financial Position and Promising SAB-142 Pipeline Merit Buy Rating
TipRanksApr 4 02:35 ET
SAB Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.
SAB Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 2 08:50 ET
Express News | HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $6
Moomoo 24/7Apr 2 08:40 ET
SAB Biotherapeutics GAAP EPS of -$7.64 Misses by $3.43, Revenue of $2.24M Beats by $1.12M
Seeking AlphaMar 29 07:17 ET
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed
GlobeNewswireMar 29 07:15 ET
SAB Biotherapeutics, Navy Medical Research Command Initiate Safety Study for Influenza Treatment; Shares Decline
SAB Biotherapeutics (SABS) said Monday that the Navy Medical Research Command will conduct a safety study of SAB-176, a potential treatment for influenza type A and B, as part of a research and develo
MT NewswiresMar 25 13:17 ET
SAB Biotherapeutics Announces Clinical Partnership With Naval Medical Research Center to Advance Potential Influenza Treatment
SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is
GlobeNewswireMar 25 10:15 ET
SAB Biotherapeutics Secures Leadership With New Executive Contracts
TipRanksMar 8 16:42 ET
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing
GlobeNewswireFeb 23 08:00 ET
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing
GlobeNewswireFeb 8 08:00 ET
No Data
No Data